NCT00132769View on ClinicalTrials.gov

A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients (MK-0873-012)(COMPLETED)

PHASE2CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
Rheumatoid Arthritis
Interventions
DRUG

MK-0873

MK-0873 1.25 mg twice daily for 12 weeks

DRUG

Comparator: Placebo

Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00132769 - A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients (MK-0873-012)(COMPLETED) | Biotech Hunter | Biotech Hunter